Lincosamides Drugs

Drug classification： These drugs include two varieties, lincomycin and its semi-synthetic derivatives clindamycin.
Mechanism： Lincosamides mainly act on the 50s ribosomal subunit of bacteria, inhibiting peptide chain extension, interfering protein synthesis of this bacteria and it is a growth phase inhibitor. Antibacterial spectrum is similar to erythromycin, but narrower. The antibacterial spectrums mainly include:
① only staphylococcus (including penicillin-resistant strains), Streptococcus, diphtheria bacillus, Bacillus anthracis and other Gram-positive bacteria.
② anaerobic bacteria, including Bacteroides fragilis, Fusobacterium, digestive bacteria, digestive streptococcus, Clostridium perfringens and so on.
③ Gram-negative aerobic bacteria such as Haemophilus influenzae, Neisseria and Mycoplasma genus which are resistant to this class. Bacteria have complete cross-resistance to lincomycin and clindamycin, and some cross-resistance to erythromycin.
 Clinical： These drugs are mainly used for anaerobic bacteria and Gram-positive cocci caused by a variety of infections such as pneumonia, endocarditis, cellulitis, erysipelas, urinary tract infections, and it is a first choice for anaerobic Bacteria-induced infections and Staphylococcus aureus osteomyelitis.